Compare CETY & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CETY | KALA |
|---|---|---|
| Founded | 1993 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.3M | 13.3M |
| IPO Year | 2020 | 2017 |
| Metric | CETY | KALA |
|---|---|---|
| Price | $1.02 | $0.52 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 24.4K | ★ 353.5K |
| Earning Date | 05-19-2026 | 04-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 67.39 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $957,633.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.18 | $0.07 |
| 52 Week High | $3.05 | $20.58 |
| Indicator | CETY | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 51.08 | 30.22 |
| Support Level | $0.71 | $0.10 |
| Resistance Level | $1.02 | $0.72 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 27.05 | 2.92 |
Clean Energy Technologies Inc develop renewable energy products and solutions and establish partnerships in renewable energy that make environmental and economic sense. Its segments are Waste Heat Recovery Solutions - It recycle wasted heat produced in manufacturing, waste to energy and power generation. Waste to Energy Solutions - It convert waste products created in manufacturing, agriculture, wastewater treatment plants and other industries to electricity, renewable natural gas hydrogen and bio char. Engineering, Consulting and Project Management Solutions - It provide power generation, waste to energy, and heat recovery, Procurement and Construction (EPC) services to municipal and industrial customers. It generates majority of revenue from United States followed by International.
Kala Bio Inc is a clinical-stage biopharmaceutical company dedicated to the research, development and commercialization of inventive therapies for rare and severe diseases of the front and back of the eye. It main product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.